Abstract: Pantoprazole is a proton pump inhibitor that is commonly used in the treatment of peptic ulcer disease (PUD) and metabolized by cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4. Pantoprazole is a substrate for multi-drug resistance protein 1 (MDR1). Single nucleotide polymorphisms (SNPs) in CYP2C19, CYP3A4 and MDR1 affect enzyme activity or gene expression of proteins and may alter plasma pantoprazole concentrations and treatment success in PUD. In this study, we aimed to investigate the association between genetic polymorphisms in CYP2C19, CYP3A4 and MDR1 and pharmacokinetics of pantoprazole and therapeutic outcome in patients with either Helicobacter pylori-associated [H.P. Genotyping was performed by using PCR-RFLP and DNA sequencing. Among patients appearing for follow-up examination (n = 105), the eradication rate for H. pylori was 82.8% (n = 87). The median pantoprazole plasma concentrations in poor metabolizers (PM), rapid metabolizers (RM) and ultrarapid metabolizers (URM) were 2.07, 1.69 and 1.28 lg/ml, respectively (p = 0.04). CYP3A4*1G and *22 polymorphisms did not affect plasma pantoprazole concentrations and H. pylori eradication rate. The MDR1 genetic polymorphisms did not affect plasma pantoprazole concentrations. MDR1 3435CC-2677GG-1236CC haplotype carriers had lower H. pylori eradication rate (60%) than the remaining subjects (84.9%) while the difference was not statistically significant (p = 0.07). In conclusion, while CYP2C19 genetic polymorphisms significantly affected plasma pantoprazole concentrations, polymorphisms of CYP2C19, CYP3A4 and MDR1 did not affect H. pylori eradication rates.
Peptic ulcer disease (PUD) is a disease of the gastrointestinal tract characterized by mucosal damage secondary to pepsin and gastric acid secretion and chronic inflammation due to Helicobacter pylori infection. H. pylori is essential in the pathogenesis and recurrence of PUD in most cases. Therefore, treatment of PUD consists of combination therapies with antibiotics for H. pylori eradication and acid-suppressive drugs for mucosal healing [1] .
Pantoprazole is a proton pump inhibitor (PPI) that is commonly used in combination with antibiotics in the treatment of peptic ulcer disease. PPIs are pro-drugs that are metabolized to reactive sulphonamide cations, which then covalently bind to the proton transporter to inactivate the protein [2] . Pantoprazole is largely metabolized by hepatic CYP2C19 and CYP3A4 enzymes [3, 4] . CYP450 genetic polymorphisms affect the enzyme activity and gene expression [5, 6] . Therefore, SNPs in CYP2C19 and CYP3A4 gene may alter plasma pantoprazole concentrations and treatment success in PUD.
CYP2C19 plays an important role in the metabolism of PPIs as well as antidepressants, anti-epileptic agents and some other drugs. There are more than 40 known genetic polymorphisms in the CYP2C19 gene and the most common variants are *2, *3 and *17 polymorphisms in Caucasians [7, 8] . *2 and *3 alleles are associated with poor metabolizer and *17 allele with ultrarapid metabolizer phenotypes. The frequency of *2, *3 and *17 alleles was found previously as 10%, 0% and 24.4%, respectively, in Turkey [9] . The half-life of pantoprazole is significantly increased in individuals that have *2 and *3 alleles, and the treatment response to pantoprazole is decreased in individuals with *17 allele [10, 11] .
CYP3A enzymes are responsible for metabolism of major drug groups. More than 40 polymorphisms for CYP3A4 have been identified, and the enzyme activities differ substantially among individuals [11] . CYP3A4*1G allele was reported as gain-of-function polymorphism, but this finding is controversial. CYP3A4*22 allele was associated with decreased enzyme expression and activity. The frequency of *1B, *1G and *22 alleles have been reported as 5.4%, 8.9% and about 5.0-7.0%, respectively, in Caucasians [12, 13] .
MDR1 (P-glycoprotein, ABCB1) is a drug transporter protein expressed in many tissues particularly in blood-brain and blood-testis barriers. Miscellaneous drugs such as antineoplastics, antiarrhythmics, HIV protease inhibitors and PPIs are substrates of MDR1. Genetic polymorphisms of MDR1 alter pharmacokinetics of these substrates and may be associated Author for correspondence: R. Ozgur Karaca, Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey (e-mail ozgurragip@hotmail.com).
with the drug resistance in treatment of various diseases with drugs including PPIs [14, 15] . Among clinically important genetic variants 1236C>T (rs1128503), 3435C>T (rs1045642) and 2677G>T/A (rs2032582) substitutions have been largely investigated. MDR1 genotypes were associated with inflammation level due to H. pylori infection in gastric mucosa [16] .
In this study, we aimed to investigate the association between genetic polymorphisms of CYP2C19, CYP3A4, MDR1 genes and pharmacokinetics of pantoprazole and therapeutic outcome in patients with either Helicobacter pyloriassociated [H.P.(+)] PUD or gastritis. A total of 194 patients newly diagnosed with either H.P.(+) PUD or gastritis were included in the study. Esophagogastroduodenoscopy and histopathological examination of biopsy-based test was performed to the patients with dyspepsia complaints for the diagnosis of H.P.(+) PUD and gastritis. Patients aged between 18 and 65 years were included the study. The patients with history of hiatal hernia, transplantation, gastrointestinal system neoplasm, pyloric stenosis caused by malign or benign aetiology, past H. pylori eradication treatment, liver or kidney disease, known hypersensitivity to PPIs, any substance/ drug dependency, pregnancy suspicion, surgical operation that possibly affected drug pharmacokinetic and patients with bad general medical condition were excluded from the study.
Methods

Patients
Patients diagnosed to have H. pylori gastritis received 40 mg pantoprazole orally on an empty stomach for the first time. Ten microlitres of venous blood was drawn at 3 hr after the dose for phenotyping [17] . The patients were prescribed 2-week treatment protocol for H. pylori gastritis including 40 mg pantoprazole two times a day, 300 mg bismuth four times a day and 1 g amoxicillin two times a day in the first week and 40 mg pantoprazole two times a day, 300 mg bismuth four times a day, 500 mg metronidazole three times a day and 500 mg tetracycline four times a day in the second week. Drug treatment was the same for all patients regardless of age, gender and body-weight. Four weeks after H. pylori gastritis treatment, the patients were called for control. Plasma pantoprazole concentrations were measured, and CYP2C19, CYP3A4 and MDR1 polymorphisms were genotyped.
Genotyping. Genomic DNA was extracted from peripheral venous blood using the QIAamp DNA Blood Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Genotyping was performed by a PCR-RFLP method described elsewhere for the CYP2C19*2, *3, *17, MDR1 3435C>T, 2677G>T/A polymorphisms [9, 18] and a new PCR-RFLP method for MDR1 1236C>T, CYP3A4*1G and Sanger sequencing method for the CYP3A4*22 polymorphism. The amount and concentration of substances used in PCR were 100 ng of genomic DNA, 100 pmol of each deoxyribonucleotide triphosphate (dNTP), 12.5 pmol of each primer, 2 mM magnesium chloride (MgCl2), 19 buffer and 2.5 U Taq polymerase (New England Biolabs GmbH, Frankfurt, Germany), and PCRs were performed in a total volume of 25 ll. The details of primers, annealing temperature, restriction endonucleases and fragments are given in table 1. PCR cycles were performed by a thermal cycler Applied Biosystems 2720 model (Waltham, MA, USA).
Fragments obtained from restriction reactions were separated by 3% agarose gel electrophoresis, and imaging was performed by Kodak Gel Logic Imaging System (Kodak, Rochester, NY, USA). CYP3A4*22 polymorphism was investigated using Sanger sequencing. CYP3A4*22 polymorphism-specific sense and antisense primer sequences were designed as 5 0 -CTGAAGCACAGTGCTTACCCAT-3 0 and 5 0 -GGTGCCAGTGATGCAGCT-3 0 , respectively. PCR conditions were as follows: an initial denaturation step of 94°C for 5 min. followed by 35 cycles of 94°C for 30 sec., 65°C for 30 sec. and 72°C for 30 sec. The final extension step was 72°C for 5 min. All fragments were purified with Exosap and Sephadex steps (GML, Wollerau, Switzerland). Purified products were analysed using Genetic Analyzer 3130 (Applied Biosystems, Waltham, MA, USA).
HPLC Measurement of plasma pantoprazole concentrations. Plasma was separated from the blood samples with centrifugation for 5 min. at 26009g. Plasma samples were stored at À20°C until analysis. Pantoprazole was kindly provided by AstraZeneca R&D (London, UK) and lansoprazole by Takeda Pharmaceutical Company (Osaka, Japan). Plasma pantoprazole concentrations were analysed by an HPLC method as described elsewhere, with slight modifications [9] . Diethyl ether-dichloromethane mixture (70:30, v/v) was used as extraction solvent. After shaking (10 min.) and centrifugation (5000 9 g for 5 min. at 4°C) of the mixture, organic phase was evaporated using rotational vacuum concentrator (Christ RVC 2-18, Osterode, Deutschland) and vacuum pump (Vacuubrand MZ 2C+AK+EK, Wertheim, Deutschland) for 20 min. at 40°C. Two hundred microlitres of mobile phase was added to the dried residue. Mobile phase consisted of phosphate buffer at pH 6.0 and acetonitrile (70:30, v/v). Forty microlitres of each vial was injected into the HPLC system (Agilent Technologies 1200 series, Santa Clara, CA, USA). Peaks were detected at wavelength of 290 nm with an UV detector. Standard curves obtained with drug-free plasma samples consisted of 10, 5, 2, 1 and 0.5 lg/ml pantoprazole concentrations. Interday and intraday coefficients of variation for pantoprazole were <10%. Lansoprazole was used as an internal standard.
Statistical analyses. Allele and genotype frequencies of CYP2C19, MDR1 and CYP3A4 among groups were compared by using chisquare test and Fisher's exact test. D'Agostino normality test was performed to measure deviation from normality. The difference in plasma drug concentrations among groups was compared by using the Mann-Whitney U-test and ANOVA test where applicable. Post hoc evaluation was performed with Dunn's multiple comparison test. Differences were considered statistically significant if p < 0.05. The averages are provided as medians with 95% confidence intervals (95% C.I.). GraphPad Prism version 6.01 for Windows (GraphPad Software, La Jolla, CA, USA) was used for statistical analysis.
Results
Among 194 patients recruited, 89 patients who did not comply with the treatment or did not contact the researchers were lost for the follow-up examination. A total of 105 patients were reexamined for H. pylori eradication after pantoprazole treatment. In 87 patients, H. pylori antigen turned negative (À) (cure group), and in 18 patients, H. pylori antigen was still positive (+) (no-cure group). Therefore, the eradication rate of 105 patients was 82.8%. There were no significant differences for gender, age and BMI between these two groups. Table 2 lists the demographic characteristics of cure and no-cure groups.
Patient demographics distributions were similar in the two patient groups (p > 0.05). The median pantoprazole plasma concentrations were 1.88 (1.49-2.41) lg/ml for the cure group and 1.59 (0.32-2.28) lg/ml for no-cure group (p = 0.42).
Comparison of plasma pantoprazole concentrations in genotypes and haplotypes. Pantoprazole plasma concentrations of 194 patients deviated from normal distribution when D'Agostino normality test was applied (p < 0.0001) and the data showed bimodal distribution ( fig. 1A) . The median pantoprazole plasma concentrations of female and male patients were 1.68 (1.14-2.27) lg/ml and 1.7 (1.45-2.07) lg/ml, respectively ( fig. 1B, The median pantoprazole plasma concentrations in CYP2C19*1*1, *2*2 and *17*17 genotype groups were 1.69 (1.27-2.21) lg/ml, 2.45 (0.08-5.26) lg/ml, 0.86 (0.03-2.24) lg/ml, respectively ( fig. 2A) . When the patients were grouped according to phenotypes predicted by genotypes, median pantoprazole plasma concentrations in poor metabolizer (PM, n = 51) (*1*2, *1*3, *2*2, *2*17 and *3*17), rapid metabolizer (RM, n = 90) (*1*1) and ultrarapid metabolizer (URM, n = 53) (*1*17 and *17*17) groups were 2.07 (1.7-2.8); 1.69 (1.27-2.21); 1.28 (0.69-1.88) lg/ml, respectively ( fig. 2B) . The difference between the URM and the remaining of the patient group was significant (p = 0.04).
Pantoprazole plasma concentration was evaluated in the CYP3A4 genotype groups. The median pantoprazole concentration of CYP3A4*1*1 (n = 85), CYP3A4*1*22 (n = 4), CYP3A4*1*1G (n = 12) and CYP3A4*1G*1G (n = 4) carriers was 1.88 (1.52-2.44) lg/ml; 1.06 (0.05-4.97) lg/ml, 0.62 (0.04-2.56) lg/ml and 1.85 (0.04-2.24) lg/ml, respectively ( fig. 3 , p = 0.31).
Patients were also grouped according to their MDR1 3435C>T, 2677G>T/A and 1236C>T genotypes ( fig. 4A-D) . Median pantoprazole plasma concentrations in MDR1 3435 CC (n = 44) and CT-TT (n = 149) carriers were 1.69 (1.37-1.88) lg/ml and 1.75 (1.28-2.21) lg/ml, respectively ( fig. 4A , p = 0.46). Median pantoprazole plasma concentration of MDR1 2677 GG (n = 42) and the remaining genotypes (n = 151) were 1.72 (1.37-2.06) lg/ml and 1.7 (1.27-2.18) lg/ml, respectively ( fig. 4B , p = 0.62). Pantoprazole plasma concentrations in MDR1 1236C>T genotype groups were 1.67 (1.24-2.06) lg/ml for CC (n = 52) and 1.72 (1.27-2.17) lg/ ml for CT and TT genotypes (n = 140) ( fig. 4C , p = 0.51). When the patients were grouped according to their MDR1 haplotypes for all three homozygous wild-type (3435CC-2677GG-1236CC) and homozygous variant (3435TT-2677TT-1236TT) alleles, median pantoprazole plasma concentrations were similar and 1.73 (1.24-2.21) lg/ml for 3435CC-2677GG-1236CC (n = 29) and 1.59 (1.06-2.46) lg/ml for 3435TT-2677TT-1236TT (n = 37) ( fig. 4D , p = 0.83).
The frequencies of CYP2C19, CYP3A4 and MDR1 polymorphisms are supplied in table 3.
Helicobacter pylori eradication. H. pylori eradication rates were evaluated according to patients' demographics (gender, age and BMI). Eradication 
Discussion
In this study, we found that plasma pantoprazole concentrations of 194 patients showed bimodal distribution ( fig. 1A ) and pantoprazole plasma concentrations of female and male patients were similar (fig. 1B) . Plasma pantoprazole concentrations were significantly altered according to activity level of CYP2C19, which is the main enzyme responsible for metabolism of pantoprazole in patients with H. pylori (+) peptic ulcer or gastritis. Poor metabolizers for CYP2C19 activity had significantly higher plasma levels of pantoprazole, as compared to patients with rapid or ultrarapid metabolism (fig. 2B) . The genetic polymorphisms of CYP3A4 and MDR1 did not affect plasma pantoprazole concentrations or H. pylori eradication rates ( fig. 3-5B,C) .
H. pylori is one of the world's most common infectious agents with a prevalence of about 80% in Turkey [19] . H. pylori eradication treatment of acid-peptic diseases consists of a combination of a PPI with antibiotics such as amoxicillin, clarithromycin, tetracycline, metronidazole and levofloxacin [20] . Despite this combination therapy, H. pylori eradication is 80% or less in many countries [21, 22] . Eradication failures have been associated with certain genetic factors such as MDR1 3435C>T polymorphism, inflammatory cytokine polymorphisms (IL-1B-511) and CYP2C19*17 allele [15, [23] [24] [25] . CYP2C19 enzyme is involved in the metabolism of not only drugs but also endogenous substances such as cytoprotective prostaglandins and genetic polymorphisms of CYP2C19 may contribute to the development of peptic ulcer by influencing the prostaglandin metabolism [25] .
Pantoprazole is metabolized by CYP2C19 and CYP3A4 and MDR1 transporter plays a major role in the distribution of this drug within the body [3, 4] . Polymorphisms in genes encoding these three proteins may affect pharmacokinetics of pantoprazole [5, 26] . In fact, we found that plasma pantoprazole concentrations of these patients showed a bimodal distribution, possible due to a genetic contribution (fig. 1A) .
Desta et al. [10] reported that CYP2C19 polymorphisms did not alter C max (the peak plasma concentration of a drug after administration) and T max (time to reach C max ) of pantoprazole but CYP2C19 polymorphisms altered the elimination half-time (t 1/2 ) of pantoprazole significantly. On the contrary, it has been found that C max value of *1*2 genotype carriers was significantly higher than *1*1 genotype carriers [17] . A study from Japan by Sim et al. [27] defined CYP2C19*17 allele, and this allele was shown to be associated with the ultrarapid metabolizer status. In CYP2C19*17 carriers, reduced antidepressant and PPI treatment response have been reported [5, 27] .
A study by Furuta et al. [15] reported that in 62 peptic ulcer patients treated with PPI and amoxicillin, the eradication rate in PMs was significantly higher than URMs, and this result has been attributed to changes in the metabolism of PPI. Our results did not show a significant difference in cure rates among CYP2C19 poor metabolizers as compared to RMs and URMs. Hunfeld et al. [26] showed that CYP2C19 genetic polymorphism affected the inhibition of gastric acid secretion by different PPIs. Changes in the metabolism of PPIs were not always associated with H. pylori eradication [26, [28] [29] [30] . In our study, the eradication rates of H. pylori in CYP2C19 phenotype groups of PM, RM and URM were 80%, 82.2% and 86.6%, respectively ( fig. 5A ). These findings suggest that CYP2C19 genetic polymorphisms might affect metabolism of pantoprazole, but not H. pylori eradication rates.
CYP3A4 is another important enzyme involved in the metabolism of pantoprazole [3] . Gene expression and activity of CYP3A4 in the liver of individuals are highly variable, and this variability affects drug pharmacokinetics [31] [32] [33] [34] . There is no study in the literature about effects of genetic polymorphisms of CYP3A4 on the pantoprazole metabolism in. In particular, *1B and *1G alleles, held responsible for the increase of the enzyme activity of CYP3A4, have been shown to increase the clearance and requirements of its substrates [13, 35] . CYP3A4*22 allele was associated with lowered CYP3A4 mRNA expression and enzyme activity [12] . Hence, these alleles may affect pantoprazole plasma concentrations and H. pylori eradication. In our study, there was no significant difference between pantoprazole plasma concentrations among CYP3A4 genotype groups ( fig. 3) . Cure rates of H. pylori for CYP3A4 genotype groups were similar. In CYP3A4*22 allele carriers, H. pylori eradication rate was 100% but this rate was not significantly different from CYP3A4*1*1 or CYP3A3*1G carriers ( fig. 5B ). In the Turkish population, there have been no previous studies on CYP3A4 *22 and *1G alleles. The frequencies of *1G and *22 were 9.5 and 1.9, respectively. These results are consistent with results from other Caucasian populations [12, 13, 33, 36] .
When MDR1 haplotype groups were analysed in our patient sample, pantoprazole plasma concentrations in patients with MDR1 3435CC-2677GG-1236CC genotype were about 50% lower as compared to the patients with MDR1 3435TT-2677TT-1236TT genotype ( fig. 4D) . Although insignificant, H. pylori eradication rate in patients with MDR1 3435TT-2677TT-1236TT genotype was higher as compared to patients with MDR1 3435CC-2677GG-1236CC genotype ( fig. 5C ). In studies on MDR1 genetic polymorphisms, higher rates of H. pylori eradication in MDR1 3435 TT genotype carriers has been shown previously [5] . MDR1 expression in the stomach has been shown to be proportional to the cyclooxygenase-2 (COX-2) enzyme expression, and MDR1 genetic polymorphisms has been shown to be associated with the severity of H. pylori inflammation and level of atrophy and metaplasia [37] .
In conclusion, our results showed that in adult patients with acid-peptic disorders, pantoprazole plasma concentrations were significantly altered by CYP2C19 metabolic activity. However, H. pylori eradication rates in patients were not affected by neither pantoprazole plasma concentrations at the third hour nor genetic polymorphisms of CYP2C19, CYP3A4, MDR1.
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